Previous studies demonstrated that the increased expression and secretion of proangiogenic factor EGFL7 could support the growth of leukemic blasts, and a high level of EGFL7 was associated with lower CR rates, shorter event-free, and OS in AML patients [32]. Here, EGFL7 is linked to acute myeloid leukemia.